Giuseppe Fallara1,2,3, Ingela Franck Lissbrant4, Johan Styrke5, Francesco Montorsi1,2, Hans Garmo3,6, Pär Stattin3. 1. Division of Experimental Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Milan, Italy. 2. Vita-Salute San Raffaele University, Milan, Italy. 3. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 4. Department of Oncology Institute of Clinical Sciences, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden. 5. Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. 6. Regional Cancer Centre, Uppsala/Örebro, Uppsala University Hospital, Uppsala, Sweden.
Abstract
INTRODUCTION: The aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and adherence to treatment. MATERIAL AND METHODS: By use of data from The National Prostate Cancer Register, The Prescribed Drug Registry and the Patient Registry, time on treatment with the abiraterone and enzalutamide was analyzed in all men with castration resistant prostate cancer (CRPC) in Sweden 2015-2019. Three time intervals between consecutive fillings, i.e. time without drug supply, were assessed. Adherence to the treatment was evaluated by use of the Medication Possession Ratio. Kaplan Meier analysis and multivariable Cox regression model were used to assess factors affecting time on treatment. RESULTS: Between January 2015 and October 2019, 1803 men filled a prescription for abiraterone and 4 534 men filled a prescription for enzalutamide. With a time interval of 30 days or less between two fillings, median time on treatment was 4.9 months (IQR 2.6-11.7) for abiraterone and 8.0 months (IQR 3.6-16.4) for enzalutamide. In sensitivity analyses, allowing for no more than 14 days without drug supply between fillings, median time on treatment was 3.9 months (IQR 2.1-9.0) for abiraterone and 5.9 months (IQR 2.8-12.1) for enzalutamide. Allowing for any time period without drug between fillings, median time on treatment was 5.7 months (IQR 2.7-14.0) for abiraterone and 9.8 months (IQR 4.4-21.0) for enzalutamide. Adherence to treatment was above 90% for both drugs. CONCLUSION: Time on treatment with abiraterone and enzalutamide was shorter in clinical practice than in randomized controlled trials and varied almost two-fold with time interval without drug. Adherence to treatment was high. The main limitation of our study was the lack of data on use of chemotherapy.
INTRODUCTION: The aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and adherence to treatment. MATERIAL AND METHODS: By use of data from The National Prostate Cancer Register, The Prescribed Drug Registry and the Patient Registry, time on treatment with the abiraterone and enzalutamide was analyzed in all men with castration resistant prostate cancer (CRPC) in Sweden 2015-2019. Three time intervals between consecutive fillings, i.e. time without drug supply, were assessed. Adherence to the treatment was evaluated by use of the Medication Possession Ratio. Kaplan Meier analysis and multivariable Cox regression model were used to assess factors affecting time on treatment. RESULTS: Between January 2015 and October 2019, 1803 men filled a prescription for abiraterone and 4 534 men filled a prescription for enzalutamide. With a time interval of 30 days or less between two fillings, median time on treatment was 4.9 months (IQR 2.6-11.7) for abiraterone and 8.0 months (IQR 3.6-16.4) for enzalutamide. In sensitivity analyses, allowing for no more than 14 days without drug supply between fillings, median time on treatment was 3.9 months (IQR 2.1-9.0) for abiraterone and 5.9 months (IQR 2.8-12.1) for enzalutamide. Allowing for any time period without drug between fillings, median time on treatment was 5.7 months (IQR 2.7-14.0) for abiraterone and 9.8 months (IQR 4.4-21.0) for enzalutamide. Adherence to treatment was above 90% for both drugs. CONCLUSION: Time on treatment with abiraterone and enzalutamide was shorter in clinical practice than in randomized controlled trials and varied almost two-fold with time interval without drug. Adherence to treatment was high. The main limitation of our study was the lack of data on use of chemotherapy.
Authors: Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg Journal: N Engl J Med Date: 2018-06-28 Impact factor: 91.245
Authors: C Lu; A Terbuch; D Dolling; J Yu; H Wang; Y Chen; J Fountain; C Bertan; A Sharp; S Carreira; W B Isaacs; E S Antonarakis; J S De Bono; J Luo Journal: Ann Oncol Date: 2020-05-05 Impact factor: 32.976
Authors: Mieke Van Hemelrijck; Annette Wigertz; Fredrik Sandin; Hans Garmo; Karin Hellström; Per Fransson; Anders Widmark; Mats Lambe; Jan Adolfsson; Eberhard Varenhorst; Jan-Erik Johansson; Pär Stattin Journal: Int J Epidemiol Date: 2012-05-04 Impact factor: 7.196
Authors: Badereddin Mohamad Al-Ali; Gero Kramer; Stephan Madersbacher; Ingrid Berger Journal: Wien Klin Wochenschr Date: 2016-09-05 Impact factor: 1.704
Authors: Walter Cazzaniga; Eugenio Ventimiglia; Massimo Alfano; David Robinson; Ingela Franck Lissbrant; Stefan Carlsson; Johan Styrke; Francesco Montorsi; Andrea Salonia; Pär Stattin Journal: Front Med (Lausanne) Date: 2019-03-22
Authors: G Procopio; V E Chiuri; M Giordano; A R Alitto; R Maisano; R Bordonaro; S Cinieri; S Rossetti; S De Placido; M Airoldi; L Galli; D Gasparro; G M Ludovico; P F Guglielmini; C Carella; P Nova; M Aglietta; L Schips; P Beccaglia; A Sciarra; L Livi; D Santini Journal: ESMO Open Date: 2022-04-08